Drug Profile
Ghrelin - TheraSource
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator TheraSource
- Developer The Feinstein Institute for Medical Research; TheraSource
- Class Peptide hormones; Radioprotectives; Vascular disorder therapies
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Acute radiation syndrome; Stroke
Highest Development Phases
- No development reported Acute radiation syndrome; Stroke
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (SC)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Stroke in USA (IV)
- 03 Aug 2016 Preclinical development in Stroke is ongoing in USA